Non-alcoholic Steatohepatitis Treatment Market size was valued at USD 6.16 billion in 2024 and is expected to cross USD 50.5 billion by the end of 2037, expanding at more than 18.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of non-alcoholic steatohepatitis treatment is estimated at USD 7.07 billion. The growth of the market is attributed to the growing number of obese people. Obesity is the main cause of fatty liver problems as it increases the accumulation of fatty tissue in the liver. In the United States, about 42% of people are obese, with black adults being about 50% fatter.
Additionally, Indians are more likely to be obese in 2019–21 than in 2015–2016. Compared to one in five people in the past, about one in four is overweight today. In addition, positive results from clinical trials of therapeutic drugs are believed to be among the factors driving the growth of the non-alcoholic steatohepatitis (NASH) drugs market. For example, traces in an analysis of Intercept's phase 3 recovery study of obeticholic acid showed that some positive substances, such as B. OCA 25 mg, achieved important goals of improving liver fibrosis without worsening NASH. In addition, OCA 25 mg demonstrated a double response rate in reducing liver fibrosis without worsening NASH compared to placebo.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
18.2% |
|
Base Year Market Size (2024) |
USD 6.16 billion |
|
Forecast Year Market Size (2037) |
USD 50.5 billion |
|
Regional Scope |
|
Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Others)
The vitamin E and pioglitazone segment in the non-alcoholic steatohepatitis treatment market is estimated to gain the largest revenue share in the year 2037. The growth of the segment can be attributed to the increasing effectiveness of vitamin E and pioglitazone in treating NASH patients. In an experiment of using pioglitazone for treating 52 NASH patient with type-II diabetes and 49 with prediabetes. The result showed that compared to 46% of patients without diabetes, 48% of type 2 diabetes patients achieved the primary outcome. Compared to 26% of people without type 2 diabetes, resolution of NASH was achieved in 44% of those patients. On the other hand, few experiments have shown that a dose of 800 IU per day of vitamin E is beneficial for active NASH adult patients without any form of diabetes.
Distribution Channel (Hospital Pharmacies, Retail & Specialty Pharmacies)
Non-alcoholic steatohepatitis treatment market from the retail & specialty pharmacies segment is expected to garner a significant share in the year 2037. NASH is an chronic disease that forces patient to be on medication for a very long period, that boost the sales of NASH drugs from the retail pharmacies. NASH therapeutic should be continuously received by the patient otherwise it can lead to severe issues, such as liver failure, liver transplantation, and even liver cancer. In the cases of liver cancer, NASH is combined with liver cancer therapeutics which reduces its efficacy. Therefore, it is important to continue the course of drugs for NASH. The segment growth is major attributed to homecare facilities that are connected to retail pharmacies, which in turn boost the demand for off-label drugs. Few pharmaceutical corporations have indicated that the total medication market for NASH is worth around USD 35 Billion.
Our in-depth analysis of the global NASH treatment market includes the following segments:
|
Distribution Channel |
|
|
Drug Type |
|
North American Market Forecast
The non-alcoholic steatohepatitis treatment market in the North American region is projected to hold the largest market share of 40% by the end of 2037. The growth of the market can be attributed majorly to the rising cases of non-alcoholic fatty liver diseases. Around 80 million to 100 million Americans are affected by non-alcoholic fatty liver disease. It has become the leading cause for liver transplant, surpassing hepatitis C. Moreover, out of total people suffering with NAFLD, around 30 million are affected by specifically non-alcoholic steatohepatitis (NASH). Additionally, the rising expenditure on the treatment of NASH patients is expected to boost the market growth in North America. The annual healthcare expense for NASH in the United States is around USD 5 billion. The expenditure entails various facilities, including testing, treatment, transplants, and hospitalization.
European Market Statistics
The non-alcoholic steatohepatitis treatment market in the Europe region is projected to hold the second largest share during the forecast period. The segment is expected to grow at a CAGR of 18.6% over the forecast period. Moreover, the market in Europe generated a revenue of USD 1,485.7 million in 2022. The market growth in the region is credited to the rise in the size of the obese population. According to the WHO European Regional Obesity Report 2022, 59% of adults and roughly one in three children (29% of boys and 27% of girls) in the region are overweight or obese.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?